Amphotericin B colloidal dispersion

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 3, 2000, Pages 475-488

  Patel, Robin ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amphotericin B cholesteryl sulphate complex; Amphotericin B colloidal dispersion; Amphotericin B deoxycholate; Fungal infections; Fungi

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT;

ANIMAL; CLINICAL TRIAL; COLLOID; HUMAN; MICROBIOLOGY; MYCOSIS; REVIEW;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS; COLLOIDS; HUMANS; MYCOSES;

EID: 0034157926     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.3.475     Document Type: Review

References (63)

1. SOKOL-ANDERSON ML, BRAJTBURG J, MEDOFF G: Amphotericin-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. (1986) 154:76-83.
2. BRAJTBURG J, POWDERLY WG, KOBAYASHI GS, MEDOFF G: Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. (1990) 34:183-188.
3. CHIA JKS, MCMANUS EJ: In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob. Agents Chemother. (1990) 34:906-908.
4. GIGLIOTTI F, SHENEP JL, LOTT L, THORNTON D: Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis. (1987) 156(5):784-789.
5. GELFAND JA, KIMBALL K, BURKE JF et al.: Amphotericin B treatment of human mononuclear cells results in secretion of tumor necrosis factor and IL-1. Clin. Res. (1988) 36:456A.
6. ARNING M, KLICHE KO, HEERSONDERHOFF AH, WEHMEIER A: Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses (1995) 38(11-12):459-465.
7. LE Y, RANA KZ, DUDLEY MN: Amphotericin B-associated hypertension. Ann. Pharmacother. (1996) 30(7-8):765-767.
8. BARLOWS TGR, LUBER AD, JACOBS RA, GUGLIELMO BJ: Hypothermia following the intravenous administration of amphotericin B. Clin. Infect. Dis. (1996) 23(5):1187-1188.
9. LEVY M, DOMARATZKI J, KOREN G: Amphotericin-induced heart-rate decrease in children. Clin. Pediat. (1995) 34(7):358-364.
10. SAWAYA BP, BRIGGS JP, SCHNERMANN J: Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. (1995) 6(2):154-164.
11. SABRA R, BRANCH RA: Amphotericin B nephrotoxicity. Drug Safety (1990) 5(2):94-108.
12. BUTLER WT, BENNETT JE, ALLING DW, WERTLAKE PT, UTZ JP, HILL GJI: Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann. Intern. Med. (1964) 61:175-187.
13. BURGESS JL, BIRCHALL R: Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am. J. Med. (1972) 53(1):77-84.
14. CHENG JT, WITTY RT, ROBINSON RR, YARGER WE: Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Intern. (1982) 22(6):626-633.
15. KOLDIN MH, KOBAYASHI GS, BRAJTBURG J, MEDOFF G: Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob. Agents Chemother. (1985) 28(1):144-145.
16. WASAN KM, LOPEZ-BERESTEIN G: The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J. Drug Target. (1994) 2(5):373-380.
17. WASAN KM, KENNEDY AL, CASSIDY SM et al.: Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. (1998) 42(12):3146-3152.
18. WASAN KM, CONKLIN JS: Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. (1997) 24(1):78-80.
19. LIN AC, GOLDWASSER E, BERNARD EM, CHAPMAN SW: Amphotericin B blunts erythropoietin response to anemia. J. Infect. Dis. (1990) 161(2):348-351.
20. MACGREGOR RR, BENNETT JE, ERSLEV AJ: Erythropoietin concentration in amphotericin B-induced anemia. Antimicrob. Agents Chemother. (1978) 14(2):270-273.
21. WALSH TJ, LYMAN CA: New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Cancer Treat. Res. (1995) 79:113-148.
22. LI PK, LAI KN: Amphotericin B induced ocular toxicity in cryptococcal meningitis. Br. J. Ophthalmol. (1989) 73(5):397-398.
23. DEVUYST O, GOFFIN E, VAN YPERSELE DE STRIHOU C: Recurrent hemiparesis under amphotericin B for Candida albicans peritonitis. Nephrol., Dialysis, Transplant. (1995) 10(5):699-701.
24. LIU JS, CHANG YY, CHEN WH, CHEN SS: Amphotericin B-induced leukoencephalopathy in a patient with cryptococcal meningitis. J. Formosan Med. Assoc. (1995) 94(7):432-434.
25. HARTSEL S, BOLARD J: Amphotericin B: new life for an old drug. Trends Pharm. Sci. (1996) 17(12):445-449.
26. WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. (1999) 340(10):764-771.
27. WHITE MH, BOWDEN RA, SANDLER ES et al.: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1998) 27(2):296-302. Randomised, double-blind clinical trial of ABCD versus amphotericin B deoxycholate in the empirical treatment of febrile neutropenia.
28. GRAYBILL JP: Lipid formulations for amphotericin B: does the emperor need new clothes? Ann. Int. Med. (1996) 124(10):921-923.
29. ORAVCOVA E, MISTRIK M, SAKALOVA A et al.: Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy (1995) 41(6):473-476.
30. SPEELEVELD E, GORDTS B, VANLANDUYT HW, DEVROEY C, RAESWUYTACK C: Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses (1996) 39(1-2):37-40.
31. WARNOCK DW: Amphotericin B: an introduction. J. Antimicro. Chemother. (1991) 28:27-38.
32. CROSS JT, JR., HICKERSON SL, YAMAUCHI T: Antifungal drugs. Pediat. Rev. (1995) 16(4):123-129.
33. STERLING TR, GASSER RA, JR., ZIEGLER A: Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. (1996) 23(1):187-188.
34. GEORGOPAPADAKOU NH, WALSH TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. (1996) 40:279-291.
35. JOHNSON EM, OJWANG JO, SZEKELY A, WALLACE TL, WARNOCK DW: Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. (1998) 42(6):1412-1416.
36. HANSON LH, STEVENS DA: Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. (1992) 36(2):486-488.
37. CLEMONS KV, STEVENS DA: Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. (1991) 35(9):1829-1833. Study of the comparative activity of ABCD and amphotericin B deoxycholate in treatment of experimental coccidioidomycosis.
38. ALLENDE MC, LEE JW, FRANCIS P et al.: Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. (1994) 38(3):518-522. Study of the activity of ABCD in treatment of experimental aspergillosis.
39. HOSTETLER JS, CLEMONS KV, HANSON LH, STEVENS DA: Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. (1992) 36(12):2656-2660.
40. CLEMONS KV, STEVENS DA: Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. (1998) 42(4):899-902. Comparative study of the lipid formulations of amphotericicn B for the treatment of experimental cryptococcosis.
41. FIELDING RM, SMITH PC, WANG LH, PORTER J, GUO LS: Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. (1991) 35(6):1208-1213.
42. SANDERS SW, BUCHI KN, GODDARD MS, LANG JK, TOLMAN KG: Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. (1991) 35(6):1029-1034.
43. KAN VL, BENNETT JE, AMANTEA MA et al.: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. (1991) 164(2):418-421.
44. LEENDERS AC, DE MARIE S: The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia (1996) 10(10):1570-1575.
45. BOWDEN RA, CAYS M, GOOLEY T, MAMELOK RD, van Burik JA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. (1996) 173(5):1208-1215. ABCD clinical trial.
46. NOSKIN GA, PIETRELLI L, COFFEY G, GURWITH M, LIANG LJ: Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin. Infect. Dis. (1998) 26(2):461-467. Analysis of results of candidaemia treatment with ABCD.
47. ANAISSIE EJ, MATTIUZZI GN, MILLER CB et al.: Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob. Agents Chemother. (1998) 42(3):606-611. ABCD clinical trial.
48. OPPENHEIM BA, HERBRECHT R, KUSNE S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. (1995) 21(5):1145-1153. ABCD clinical trial.
49. WHITE MH, ANAISSIE EJ, KUSNE S et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. (1997) 24(4):635-642. Analysis of results of aspergillosis treatment with ABCD versus amphotericin B deoxycholate.
50. FIELDING RM, SINGER AW, WANG LH, BABBAR S, GUO LS: Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. (1992) 36(2):299-307.
51. AMANTEA MA, BOWDEN RA, FORREST A, WORKING PK, NEWMAN MS, MAMELOK RD: Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob. Agents Chemother. (1995) 39(9):2042-2047.
52. GURWITH M, MAMELOK R, PIETRELLI L, DU MOND C: Renal sparing by amphotericin B colloidal dispersion: Clinical experience in 572 patients. Chemotherapy (1999) 45(Suppl. 1):39-47. Analysis of nephrotoxicity of ABCD.
53. NOSKIN G, PIETRELLI L, GURWITH M, BOWDEN R: Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant. (1999) 23(7):697-703. Analysis of results of use of ABCD in bone marrow transplant recipients.
54. HERBRECHT R, LETSCHER V, ANDRES E, CAVALIER A: Safety and efficacy of amphotericin B colloidal dispersion - an overview. Chemotherapy (1999) 45(Suppl. 1):67-76.
55. DUPONT B: Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Candida spp. Chemotherapy (1999) 45(Suppl. 1):27-33.
56. MOSES AE, RAHAV G, BARENHOLZ Y et al.: Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin. Infect. Dis. (1998) 26(6):1430-1433.
57. STEVENS DA: Overview of amphotericin B colloidal dispersion (amphocil). J. Infect. (1994) 1:45-49.
58. DIETZE R, MILAN EP, BERMAN JD et al.: Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis. (1993) 17(6):981-986.
59. BERMAN J, DIETZE R: Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion. Chemotherapy (1999) 1:54-66.
60. DIETZE R, FAGUNDES SM, BRITO EF et al.: Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Transactions R. Soc. Trop. Med. Hygiene (1995) 89(3):309-311.
61. JOHNSON JR, KANGAS PJ, WEST M: Serious adverse event after unrecognized substitution of one amphotericin B lipid preparation for another. Clin. Infect. Dis. (1998) 27(5):1342-1343.
62. DIETZE R, FOWLER VG, JR., STEINER TS, PECANHA PM, COREY GR: Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis. Am. J. Trop. Med. Hygiene (1999) 60(5):837-839.
63. ANAISSIE EJ, DAROUICHE RO, ABI-SAID D et al.: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. (1996) 23(5):964-972.